Next Article in Journal
Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature
Previous Article in Journal
XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
Previous Article in Special Issue
Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy
Open AccessEditorial

Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases

1
Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada
2
The Friends of Garrett Cumming Research & Muscular Dystrophy Canada, HM Toupin Neurological Science Research Chair, Edmonton, AB T6G 2H7, Canada
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(3), 129; https://doi.org/10.3390/jpm10030129
Received: 6 September 2020 / Accepted: 14 September 2020 / Published: 16 September 2020
With the development of novel targeted therapies, including exon skipping/inclusion and gene replacement therapy, the field of neuromuscular diseases has drastically changed in the last several years. Until 2016, there had been no FDA-approved drugs to treat Duchenne muscular dystrophy (DMD), the most common muscular dystrophy. However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the start of a therapeutic revolution in neuromuscular diseases. However, the studies also made clear that these therapies are still far from a cure. Personalized genetic medicine for neuromuscular diseases faces several key challenges, including the difficulty of obtaining appropriate cell and animal models and limited its applicability. This Special Issue “Molecular Diagnosis and Novel Therapies for Neuromuscular/Musculoskeletal Diseases” highlights key areas of research progress that improve our understanding and the therapeutic outcomes of neuromuscular diseases in the personalized medicine era. View Full-Text
Keywords: Duchenne/Becker muscular dystrophy (DMD/BMD); amyotrophic lateral sclerosis (ALS); viltolarsen; eteplirsen; golodirsen; phosphorodiamidate morpholino oligomers (PMOs); exon skipping; CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 (CRISPR associated protein 9)-mediated genome editing; multiplex ligation amplification (MLPA); next-generation sequencing (NGS) Duchenne/Becker muscular dystrophy (DMD/BMD); amyotrophic lateral sclerosis (ALS); viltolarsen; eteplirsen; golodirsen; phosphorodiamidate morpholino oligomers (PMOs); exon skipping; CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 (CRISPR associated protein 9)-mediated genome editing; multiplex ligation amplification (MLPA); next-generation sequencing (NGS)
MDPI and ACS Style

Maruyama, R.; Yokota, T. Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases. J. Pers. Med. 2020, 10, 129.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop